Condition
Asymptomatic Malaria
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (2)
Trial Status
Completed2
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07798583Phase 3Not Yet Recruiting
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
NCT05440773Not ApplicableUnknownPrimary
Emptying Malaria Reservoirs to Accelerate Malaria Elimination in High Transmission Settings
NCT02259426Phase 3Completed
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
NCT01935882Phase 2Completed
Low Dose Primaquine for Clearance of Gametocytes
Showing all 4 trials